NALIRIFOX in the treatment of metastatic pancreatic cancer: good clinical response at a reduced dose –⁠ a case report

Czech version

Authors: J. Vidulin ^1,2; D. Ondruš ²; Z. Miklátková ¹; F. Kohútek ¹; B. Bystrický ¹
Authors‘ workplace: Onkologická klinika FZ TU Alexandra Dubčeka a FN Trenčín ¹; I. onkologická klinika LF UK a Onkologický ústav sv. Alžbety, Bratislava ²
Published in: Gastroent Hepatol 2026; 80(4): 326-330
Category: Gastrointestinal Oncology: Case Report
doi: https://doi.org/10.48095/ccgh2026326

Overview

Introduction: Pancreatic adenocarcinoma is one of the most aggressive malignancies and is associated with a very poor prognosis. The novel chemotherapy regimen NALIRIFOX demonstrated improved overall survival and progression-free survival in the NAPOLI-3 trial in the first-line treatment of metastatic disease. Case report: We present a case of a 59-year-old patient with initially metastatic pancreatic adenocarcinoma who was started on palliative chemotherapy with the NALIRIFOX regimen. Despite repeated dose reductions due to treatment--related toxicity, a partial response was achieved, followed by long-term disease stabilisation. The overall duration of treatment response exceeded 18 months. Conclusion: This case report demonstrates the efficacy and clinical applicability of the NALIRIFOX regimen in real-world practice. It also highlights the importance of treatment individualisation and toxicity management, which enable long-term administration of therapy and sustained disease control.

Keywords:

pancreatic adenocarcinoma – metastatic disease – NALIRIFOX regimen – palliative chemotherapy – case report

Sources

1. Conroy T, Pfeiffer P, Vilgrain V. et al. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (11): 987–1002. doi: 10.1016/j.annonc.2023.08.009.

2. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 (19): 1817–1825. doi: 10.1056/NEJMoa1011923.

3. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18): 1691–1703. doi: 10.1056/NEJMoa1304369.

4. Goldstein D, El-Maraghi RH, Hammel P et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015; 107 (2): dju413. doi: 10.1093/jnci/dju413.

5. Wainberg ZA, Melisi D, Macarulla T et al. NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol 2023; 41 (4_suppl): LBA661. doi: 10.1200/JCO.2023.41.4_suppl.LBA661.

6. Patel AJ, Laursen AA, Cockrum P et al. Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: a post hoc analysis of NAPOLI-3. J Clin Oncol 2025; 43 (4_suppl.): 716. doi: 10.1200/JCO.2025.43.4_suppl.716.